HealthMore in Health→
FDA Approves J&J's Icotyde, a New Psoriasis Pill With $5B+ Potential
Key Takeaways
- FDA approved J&J's icotrokinra (Icotyde) for moderate-to-severe plaque psoriasis in patients aged 12 and older
- Icotyde is an oral small molecule inhibitor, offering a pill alternative to existing injectable biologic treatments
- J&J projects peak annual sales exceeding $5 billion, making it a potential megablockbuster
- Psoriasis affects 125 million people worldwide and the oral format could reach patients who avoid injections
DE
DT Editorial Team··3 min read·via endpoints.news